Parkinsons

Announcing Parkinson’s Clinical Trial

For Individuals Experiencing End of Dose Wearing Off

This trial is to evaluate the safety and efficacy of the investigational product tozadenant as adjunctive therapy in levodopa-treated patients with end of dose wearing off.
Parkinson's Disease Clinical Trials

Tozadenant has a novel mechanism of action which, if proven safe and efficacious and approved by the FDA, could represent the first new treatment modality for Parkinson’s disease in more than 20 years.

Participants must:

  • Be between the ages of 30 & 80
  • Have a good response to levodopa and be taking at least 4 doses of a levodopa containing medication per day
  • Be taking levodopa continuously for at least the previous 12 months and experiencing some daily (24-hour clock) OFF time

Study-related office visits, laboratory work and medication are at
no cost.

To learn more about this trial and see if you qualify to participate, Click Here

Clinical Research Study for Individuals with Parkinson’s Disease
Protocol Title Clinical Research Study for Individuals with Parkinson’s Disease
Summary This Phase III study is testing an investigational form of a currently marketed oral medication for Parkinson’s disease.

Currently approved extended-release, oral carbidopa-levodo products are absorbed over 4-6 hours. However, the absorption appears to be delayed and may require supplemental doses of immediate release carbidopa-levodo. Therefore, there is a need to develop an improved oral extended release product that can consistently deliver fast and stable levodopa plasma concentrations.

IPX066, the medication being tested in this study, is an oral investigational extended-release product intended to produce rapid and sustained plasma concentrations of levodopa over 6 hours following a single oral dose.

If you are eligible to participate in this 22-week trial, you will need to visit the research study site for an initial assessment visit and up to 8 more times on week’s 1, 3, 5, 7, 9, 12, 17, and 22 of the study. You will receive all study-related medical care, medication, and laboratory work at no financial cost to you for the duration of your participation in the study and you may-be provided transportation costs for attending the study visits.
Therapeutic Area Parkinson’s Disease
Age Range Minimum Age : 30
Purpose This clinical study is designed to evaluate the safety and efficacy of the investigational drug IPX066 for individuals with Advanced Parkinson’s Disease.
Who is Eligible? To participate you must:

  • Have a confirmed diagnosis of Parkinson’s Disease
  • Be at least 30 years old at the time of your Parkinson’s Disease diagnosis
  • Currently be taking the medication carbidopa-levodopa (e.g. SINEMET®)

Register now as a patient to take a brief questionnaire to determine if you qualify to participate in this clinical trial.